AstraZeneca PLC Valuation
| AZNN Stock | MXN 1,384 6.50 0.47% |
At this time, the firm appears to be overvalued. AstraZeneca PLC shows a prevailing Real Value of 1217.66 per share. The current price of the firm is 1383.5. Our model approximates the value of AstraZeneca PLC from analyzing the firm fundamentals such as Profit Margin of 0.07 %, current valuation of 4.74 T, and Return On Equity of 0.0863 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Stock. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1383.5 | Real 1217.66 | Hype 1383.5 |
The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Total Value Analysis
AstraZeneca PLC is presently anticipated to have takeover price of 4.74 T with market capitalization of 4.04 T, debt of 22.96 B, and cash on hands of 15.63 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the AstraZeneca PLC fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.74 T | 4.04 T | 22.96 B | 15.63 B |
AstraZeneca PLC Investor Information
About 18.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.37. AstraZeneca PLC recorded earning per share (EPS) of 19.72. The entity last dividend was issued on the 23rd of February 2023. The firm had 2:1 split on the 27th of July 2015. Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.AstraZeneca PLC Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AstraZeneca PLC has an asset utilization ratio of 45.97 percent. This suggests that the Company is making 0.46 for each dollar of assets. An increasing asset utilization means that AstraZeneca PLC is more efficient with each dollar of assets it utilizes for everyday operations.AstraZeneca PLC Ownership Allocation
AstraZeneca PLC holds a total of 3.1 Billion outstanding shares. Almost 82.02 percent of AstraZeneca PLC outstanding shares are held by general public with 0.04 (percent) owned by insiders and only 17.94 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.AstraZeneca PLC Profitability Analysis
The company reported the revenue of 44.35 B. Net Income was 3.29 B with profit before overhead, payroll, taxes, and interest of 35.73 B.About AstraZeneca PLC Valuation
Our relative valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AstraZeneca PLC's related companies.AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. ASTRAZENECA operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 76100 people.
8 Steps to conduct AstraZeneca PLC's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AstraZeneca PLC's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AstraZeneca PLC's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AstraZeneca PLC's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AstraZeneca PLC's revenue streams: Identify AstraZeneca PLC's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AstraZeneca PLC's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AstraZeneca PLC's growth potential: Evaluate AstraZeneca PLC's management, business model, and growth potential.
- Determine AstraZeneca PLC's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AstraZeneca PLC's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.